Background: Once castration resistance is documented and secondary hormone therapy is ineffective, standard treatment of metastatic prostate cancer is docetaxel, with bisphosphonates and radiopharmaceuticals administered to treat bone symptoms. To improve outcomes, numerous studies have evaluated docetaxel in combination with other agents. Here, results for docetaxel-based combination therapy in castration-resistant prostate cancer (CRPC) are reviewed.
Prostate cancer is the second most common cancer in men, with an estimated 192 000 and 346 000 new cases diagnosed each year in the United States and Europe, respectively [1, 2] . Approximately 15% of diagnosed patients will die because of advanced metastatic disease. Androgen deprivation therapy via medical or surgical castration represents the standard treatment of patients with advanced metastatic disease, although progression typically occurs within 1-2 years of initial response [3, 4] . Secondary hormonal therapy is an option in some patients, although responses are transient with currently available agents. Prostate cancer that has progressed despite castrate levels of androgens (<50 ng/ml) is termed castrationresistant prostate cancer (CRPC), and clinical manifestations include rising prostate-specific antigen (PSA) concentration in 90%, bone metastases in 90%, substantive pain in 35%, and soft-tissue/lymph node metastases in 20% of patients [5] . Because of the high frequency of bone metastases, skeletal complications, including vertebral fractures, are responsible for a considerable proportion of patient morbidity.
front-line systemic treatment of metastatic CRPC
Docetaxel was the first chemotherapy to improve survival in CRPC, as demonstrated in two independent phase III trials reported in 2004. In the TAX 327 trial, 1006 patients received docetaxel every 3 weeks (Q3W), docetaxel weekly, or mitoxantrone, with all three arms receiving low-dose prednisone daily. Compared with mitoxantrone, docetaxel Q3W significantly extended overall survival (median 19.2 versus 16.3 months, P = 0.004) and was associated with higher rates of PSA response (i.e. 50% reduction in PSA from baseline; 45% versus 32%, P < 0.001) and pain control (35% versus 22%, P = 0.01). Patients who received docetaxel weekly experienced similar responses to docetaxel Q3W but without significantly extended overall survival (median 17.8 months) [6, 7] . In the SWOG 99-16 trial, 770 men received either docetaxel Q3W plus estramustine and dexamethasone or mitoxantrone plus prednisone [8] . Similar to TAX-327, patients in the docetaxel arm had increased survival compared with the review *Correspondence to: Dr M. D. Galsky, Comprehensive Cancer Centers of Nevada, 3730 South Eastern Avenue, Las Vegas, NV 89169, USA. Tel: +1-702-952-3412; Fax: +1-702-952-3722; E-mail: Matthew.Galsky@usoncology.com mitoxantrone arm (17.5 versus 15.6 months, P = 0.02). Following these trials, front-line docetaxel therapy (i.v. docetaxel 75 mg/m 2 Q3W plus oral prednisone 5 mg twice daily) became the standard of care for patients with metastatic CRPC [9, 10] .
Because of the high rate of bone metastases in patients with prostate cancer, including a large proportion of patients who have bone-only metastases, treatments directed specifically against the bone microenvironment are administered in CRPC. Bisphosphonates are potent inhibitors of osteoclast activity, and although prostate cancer-associated bone metastases tend to have an osteoblastic phenotype in radiographic imaging, osteoblast and osteoclast activity are both increased in most cases, reflecting the fact that both processes contribute to tumor-mediated bone effects [11] . Zoledronic acid (4 mg Q3W) is the only bisphosphonate approved for treating men with prostate cancer bone metastases, on the basis of a phase III trial showing a significant reduction in the occurrence of skeletal-related events (SREs) [12] . Effects of zoledronic acid on bone markers included a significant decrease in concentrations of urinary N-telopeptide (uNTx), a bone resorption marker, and stabilization of serum bone alkaline phosphatase (BAP), a marker of bone formation [13] .
In a recent phase II study, normalization of uNTx levels in patients with CRPC who had elevated uNTx despite ongoing bisphosphonate therapy occurred more frequently with denosumab, a receptor activator of NF-jB ligand-targeted mAb, than with ongoing bisphosphonates [14] . Results from a phase III trial of zoledronic acid versus denosumab in men with CRPC and bone metastases are expected in 2010.
docetaxel-based combination therapy
Docetaxel is a taxane that blocks microtubule activity during cell division leading to apoptosis. Preclinically, multiple classes of agents with other mechanisms of action have shown additive or synergistic activity with docetaxel. Because options for patients with CRPC are limited following docetaxel failure [15] , considerable efforts are being directed at applying potential benefits of docetaxel-based combination therapy to the clinic, aiming to increase the number and/or duration of responses. In the remainder of this review, data from phase II/III studies ( Table 1) and designs of new/ongoing phase III trials of docetaxel-based combination therapy (Table 2 ) are discussed.
tyrosine kinase inhibitors
In normal cells, tyrosine kinases mediate multiple signaling pathways responsible for cell proliferation, migration, apoptosis, and angiogenesis. Abnormal tyrosine kinase signaling has been consistently linked with tumorigenesis and drug resistance [58] . Several tyrosine kinase inhibitors (TKIs) with different target specificities are being investigated in combination with docetaxel for metastatic CRPC.
In separate phase II studies, three epidermal growth factor receptor (EGFR) inhibitors have been combined with docetaxel. In single-arm studies of gefitinib or erlotinib, PSA and tumor responses were modest, although erlotinib showed favorable survival (24.6 months) with increased toxicity [16, 17] . In a randomized double-blind study of vandetanib, a TKI of EGFR and vascular endothelial growth factor receptor (VEGFR), combined with docetaxel and prednisolone, no additional benefit was reported [18] . Further studies of EGFR inhibitors in prostate cancer are focused on disease stages earlier than CRPC.
Imatinib, an inhibitor of platelet-derived growth factor receptor (PDGFR), KIT, and ABL, was assessed in CRPC after studies showed PDGFR overexpression in a high percentage of prostate cancer bone metastases [59, 60] . In a randomized phase II trial of imatinib plus docetaxel, accrual was halted early because of gastrointestinal adverse events and efficacy data showing no therapeutic benefit compared with docetaxel alone [19] . In a phase I trial of imatinib plus docetaxel and estramustine, a high incidence of thromboembolic events halted further assessment [61] . These and other imatinib studies have failed to show a benefit for PDGFR inhibition in CRPC.
Sorafenib is a multikinase inhibitor of several targets, including VEGFR, PDGFR, RAF, and KIT, which has preclinical antiangiogenic and antiproliferative activity. In phase II studies in CRPC, single-agent sorafenib was well tolerated, and modest treatment responses and decreases in bone scan lesions were observed. Because PSA levels are often paradoxically increased in responding patients, investigators questioned if standard PSA-based end points used provided appropriate assessment [62] [63] [64] [65] [66] . Early results from a phase II trial combining sorafenib and docetaxel treatment have been reported, including complete disappearance of bone lesions in two patients [20] . Further data from this and other trials of sorafenib plus docetaxel in CRPC are awaited.
Like sorafenib, sunitinib is a multitargeted TKI of PDGFR, VEGFR, and KIT. In preclinical studies, sunitinib showed additive effects with docetaxel against prostate cancer xenografts [67, 68] . Sunitinib has shown some single-agent activity in CRPC, including patients with docetaxel resistance [69] , although in one study, 50% of patients discontinued treatment because of toxicity [70] . Encouraging data have been reported recently from a phase I/II study of sunitinib plus docetaxel and prednisone as front-line therapy for metastatic CRPC, including a median time to PSA progression of 42 weeks, confirmed RECIST-defined partial response (PR) in 33% of assessable patients, and overall survival probability at 48 weeks of 92% [21] . Longer follow-up is needed to determine median overall survival. A phase III trial of sunitinib plus prednisone versus prednisone alone in patients with docetaxel failure is ongoing (NCT00676650).
Dasatinib is a potent inhibitor of SRC and SRC family kinases. In preclinical studies, dasatinib showed antiproliferative and antimetastatic activity against prostate cancer cells, antiosteoclast activity, and increased activity in combination with docetaxel against prostate cancer growth in bone [71] [72] [73] . Data have been reported from a phase I/II study of dasatinib plus docetaxel and prednisone in patients with CRPC. Among assessable patients, 49% had a 50% PSA response, 42% had a confirmed PR, and 28% had a reduction in size and/or number of bone lesions. In bone-marker analyses, 50% had a ‡35% decrease in uNTx and 75% had a decrease in BAP [22] . In a phase II study of dasatinib monotherapy in metastatic CRPC, tumor responses were modest but uNTx and BAP concentrations were consistently reduced, with similar effects in bisphosphonate-treated and -untreated patients. In safety analyses, dasatinib administered once daily had improved tolerability compared with a twice-daily schedule [74] . To further evaluate dasatinib plus docetaxel and prednisone in metastatic CRPC, a placebo-controlled phase III trial is in progress (CA180-227), which will assess survival plus antitumor and bone effects (NCT00744497).
antiangiogenic agents
In addition to VEGFR-targeting TKIs, other inhibitors of angiogenesis have been combined with docetaxel. Bevacizumab is a recombinant anti-vascular endothelial growth factor (VEGF) antibody approved for treating advanced colorectal, non-small-cell lung, and breast cancer in combination with chemotherapy. In an early phase II study in chemotherapynaive patients with CRPC, bevacizumab plus docetaxel and estramustine resulted in a promising rate of tumor response of 53% [23] . Responses were also reported with bevacizumab plus docetaxel in patients with CRPC who had previously progressed on docetaxel [24] . A phase III trial of docetaxel and prednisone with and without bevacizumab (CALGB/ECOG-90401) has completed accrual and results are pending (NCT00110214). Aflibercept (VEGF Trap) is a soluble human VEGFR fusion protein with antiangiogenic activity. Although no phase I/II data have been reported in prostate cancer, aflibercept is also undergoing phase III evaluation in combination with docetaxel in CRPC (NCT00519285).
Thalidomide is an oral angiogenesis inhibitor with an unknown mechanism of action. In a randomized phase II study of docetaxel plus thalidomide or placebo in patients with metastatic CRPC, the thalidomide arm had numerically more 50% PSA responses (53% versus 37%; P = 0.32) and extended median overall survival (29 versus 15 months, P = 0.11). Although acceptable safety was reported, thromboembolic events occurred in 28% of patients who did not receive prophylactic anticoagulation [26] . To assess potential additive effects of inhibiting multiple angiogenic pathways, a phase II trial of bevacizumab plus thalidomide, docetaxel, and prednisone was carried out, resulting in high rates of 50% PSA response (88%) and an impressive progression-free survival (PFS) of 18.2 months [25] ; further follow-up from this study is awaited. Lenalidomide is a thalidomide derivative with immunomodulatory and antiangiogenic properties. In a phase I study in CRPC (n = 31), lenalidomide plus docetaxel showed similar 50% PSA response rates in chemotherapy-naive and previously treated patients (47% versus 50%) [75] . A phase III study of docetaxel with or without lenalidomide has recently been initiated (NCT00988208). Vadimezan (ASA404/5,6-dimethylxanthenone-4-acetic acid) is a novel vasculature-disrupting agent that has been evaluated in a randomized phase II trial in combination with docetaxel (n = 71). Compared with the docetaxel-alone arm, vadimezantreated patients had a higher 30% PSA reduction rate at 3 months (63% versus 47%) and tumor response rate (23% versus 9%) [27] .
bone-targeted agents
The endothelin (ET)-A receptor mediates the action of ET-1, a potent vasoconstrictor implicated in the pathogenesis of prostate cancer-associated bone lesions. Specifically, bone contact stimulates ET-1 production by prostate tumor cells, resulting in enhanced osteoblast activity and reduced osteoclast activity [76, 77] . Atrasentan is an ET-A receptor antagonist that enhances the effects of docetaxel against prostate cancer cells in vitro and in vivo [78, 79] . In a randomized phase II study of atrasentan monotherapy in asymptomatic CRPC, clinical effects were encouraging and included an attenuation of PSA or BAP increases [80] . However, in phase III trials in patients with metastatic or nonmetastatic CRPC, atrasentan monotherapy failed to meet primary end points of delaying disease progression [81, 82] . In a small phase I/II study of atrasentan plus docetaxel in patients with metastatic CRPC, PSA responses were less frequent than in the TAX 327 trial, which was attributed to the lack of prednisone administration. However, combination treatment significantly reduced median levels of uNTx (P = 0.04) and BAP (P = 0.0003) [28] . A phase III trial (SWOG-S0421) has been initiated to assess docetaxel/prednisone with or without atrasentan in men with CPRC and bone metastases (NCT00134056).
Zibotentan (ZD4054) is an alternative ET-A receptor antagonist. In a randomized phase II trial of zibotentan monotherapy in patients with CRPC and bone metastases who were pain free or mildly symptomatic, zibotentan at two different doses extended overall survival compared with placebo (24.5 versus 23.5 versus 17.3 months) [83] . A phase III trial of zibotentan plus docetaxel in patients with metastatic CRPC (ENTHUSE M1C) is underway (NCT00617669). radiopharmaceuticals Bone-seeking radiopharmaceuticals are a systemic treatment option for patients with CRPC who have widely metastatic painful skeletal involvement that is not responding to palliative chemotherapy or systemic analgesia and who are not candidates for localized radiotherapy [10] . The safety and antitumor potential of combining docetaxel with radiopharmaceuticals is being explored in patients with CRPC and bone metastases. In an expansion cohort of a phase I/II study of samarium 153, 44% of patients achieved a 50% PSA response, comprising 50% of taxane-naive, 55% of taxane-exposed, and 23% of taxanerefractory patients [29] . More impressive data were reported from a single-arm phase II study in which patients received consolidation therapy with docetaxel plus samarium 153 after four initial cycles of docetaxel plus estramustine. Results included a 50% PSA response in 77%, improved pain control in 69%, and median overall survival of 29 months, with few grade 3/4 hematologic adverse events [30] . A placebocontrolled phase III trial of radium 223 combined with ongoing therapy in docetaxel-ineligible patients with symptomatic CRPC and bone metastases has been initiated (NCT00699751). Phase III trials to evaluate docetaxel plus radiopharmaceuticals are needed.
inhibitors of antiapoptotic proteins
BCL-2 is an antiapoptotic protein that is highly expressed in androgen-independent prostate cancer tissue [84] . Antisense-induced down-regulation of BCL-2 has been found to increase docetaxel cytotoxicity against prostate cancer cell lines in vitro and in vivo [85, 86] . Oblimersen sodium is an antisense oligonucleotide for BCL-2 developed as a therapeutic agent. In a single-arm phase II study of oblimersen plus docetaxel in CRPC, responses were comparable with historic data for docetaxel alone [31] . In a randomized phase II study of docetaxel with or without oblimersen, similar rates of PSA and tumor response occurred in both arms, and toxicity was increased in the oblimersen arm [32] . Further evaluation of oblimersen in metastatic CRPC has been halted. AT-101 is an inhibitor of BCL-2 and related antiapoptotic proteins BCL-XL, MCL-1, and BCL-W. In patients with progressive CRPC, AT-101 has shown preliminary single-agent activity [87] . Two phase I/II studies have investigated AT-101 plus docetaxel and prednisone in CRPC. In patients with no prior chemotherapy, encouraging responses were observed, including a 50% PSA response in 67% of patients and confirmed RECIST PR in 42% [33] . Lower response rates were observed in a study of patients with prior docetaxel treatment [34] . Both studies reported generally good tolerability. A randomized phase II trial of docetaxel plus prednisone with or without AT-101 has completed accrual (n = 220), with results pending (NCT00571675).
OGX-011 is an antisense inhibitor of clusterin, an antiapoptotic chaperone protein overexpressed in docetaxelrefractory prostate cancer cell lines [88] . In a randomized phase II study in metastatic CRPC (n = 82), OGX-011 plus docetaxel/prednisone was associated with longer median overall survival than docetaxel/prednisone alone (24 versus 17 months; hazard ratio 0.61, P = 0.06), despite similar rates of PSA and tumor response. Treatment was generally well tolerated, although the OGX-011 arm experienced a higher occurrence of rigors, fever, and elevated creatinine [35] . On the basis of these encouraging findings, two phase III trials of OGX-011 plus docetaxel/prednisone as first-or second-line treatment of metastatic CRPC will be undertaken, with primary end points of overall survival and pain palliation, respectively.
cytotoxic agents
Combination treatment with docetaxel and estramustine, another microtubule-targeting chemotherapy, is supported by gene expression studies in prostate cancer cells showing that combined treatment results in an altered expression profile compared with either agent alone, including potentially beneficial effects on genes controlling proliferation, angiogenesis, invasion, and apoptosis [89] . Multiple clinical studies have explored docetaxel/estramustine combination therapy in CRPC. In a randomized phase II study (n = 95), 50% PSA responses were higher with estramustine than with docetaxel monotherapy (75% versus 40%), including PSA normalization in 32% versus 5% of patients. Additionally, more estramustine-treated patients achieved RECIST PR or complete response (CR; 47% versus 36%) and had an improvement in pain score (P = 0.01). No major differences were observed between safety profiles, although anticoagulant prophylaxis was allowed for patients at risk of thromboembolism [36] . Favorable efficacy was also reported for patients treated with estramustine plus docetaxel in other studies [37, 39] . However, in a large randomized study (n = 150) in which daily prednisone was also administered, PSA and survival outcomes were similar with or without estramustine, and estramustine was associated with higher rates of thromboembolic/cardiovascular events [38] . In a small study of docetaxel plus estramustine and zoledronic acid (n = 27), two patients developed deep venous thrombosis and died of pulmonary embolism [90] . A meta-analysis of estramustine plus chemotherapy (docetaxel, paclitaxel, ixabepilone, or vinblastine) compared with chemotherapy alone in CRPC has been carried out. Results showed that estramustine increased time to PSA progression (hazard ratio 0.74, P = 0.01) and overall survival (hazard ratio 0.77, P = 0.008; 9.5% increase at 1 year), although grade 3/4 thromboembolic adverse events were more frequent (risk ratio 4.51, P = 0.02) [91] . Overall, there is no consensus regarding the benefits of adding estramustine to docetaxel treatment, although the association with thromboembolic or cardiovascular adverse events discourages use of this combination [9] . Similarly, in a small phase I/II study of docetaxel plus vinblastine, another microtubule inhibitor, 4 of 19 patients developed venous thrombosis [48] .
Recent data for platinum-based compounds plus docetaxel are encouraging. In a phase II study, men with CRPC who had previously progressed on docetaxel achieved treatment responses with carboplatin plus docetaxel, and responses were more likely in those who had previously responded to docetaxel [42] . In a study of patients who had received up to two prior chemotherapies, oxaliplatin plus docetaxel had promising efficacy, including 50% PSA response in 69% [44] . In patients with no prior chemotherapy, picoplatin plus docetaxel and prednisone resulted in a high rate of 50% PSA response (83%), although no RECIST PRs occurred [43] . Two phase II studies have assessed combination treatment with docetaxel, carboplatin, and estramustine. In a Japanese study, PSA responses and median survival compared favorably with historic data [40] , whereas this was not observed in a USA study [41] .
Capecitabine is a DNA synthesis inhibitor that has been examined in combination with docetaxel on the basis of the mechanistic rationale that docetaxel increases expression of thymidine phosphorylase, the enzyme responsible for activating capecitabine to 5-fluorouracil [92] . In vitro, docetaxel-mediated antitumor activity against prostate cancer cells was enhanced by capecitabine metabolites [93] . Across three phase II studies of docetaxel plus capecitabine in metastatic CRPC, a 50% PSA response was achieved in 41%-76% of assessable patients, a RECIST PR or CR was reported in 24%-56%, and median overall survival was 17-22 months [45] [46] [47] . However, this has not led to a phase III trial of this combination.
immunologic agents
Several immunotherapies are being developed for CRPC. Among these, GVAX, a vaccine composed of irradiated prostate cancer cell lines engineered to secrete granulocyte macrophage colony-stimulating factor, underwent phase III assessment in combination with docetaxel in patients with symptomatic metastatic CRPC. However, this trial (VITAL-2) was terminated early because of a higher death rate in the GVAX arm [49] . Another trial (VITAL-1) compared GVAX with docetaxel in patients with asymptomatic CRPC and found no overall survival difference [94] . Development of GVAX has been halted.
other agents
Other agent classes have been combined with docetaxel for the treatment of CRPC. DN-101 is a high-dose formulation of calcitriol, the activated vitamin D analog that has antiproliferative effects against prostate cancer cells in vitro [95] . Following an early single-arm phase II study of calcitriol plus docetaxel that showed encouraging efficacy [96] , a large randomized phase II study of DN-101 plus docetaxel was carried out androgen-independent prostate cancer study of calcitriol enhancing taxotere (ASCENT). Among 250 randomized patients, efficacy was more favorable in the DN-101 group, including 50% PSA responses (63% versus 52%; P = 0.07), SRE-free survival (13.4 versus 11.9 months; P = 0.13), and overall survival [hazard ratio 0.67, P = 0.04; median 24.5 (estimated) versus 16.4 months]. Furthermore, no additional toxicity was associated with DN-101 [50] . In a subsequent phase III trial (ASCENT-2), however, an interim analysis found that the DN-101 arm had a reduced survival, leading to trial termination and clinical development of DN-101 being halted.
Diethylstilbestrol is a synthetic nonsteroidal estrogen that has activity as a secondary hormonal therapy in prostate cancer. In a small phase II study of diethylstilbestrol plus docetaxel, 21% of patients developed deep venous thrombosis despite prophylactic anticoagulant therapy [51] .
Several other agents have been combined with docetaxel in single-arm phase II trials, including celecoxib (selective cyclooxygenase-2 inhibitor) plus estramustine [52] , exisulind (inhibitor of cyclic guanosine monophosphate phosphodiesterase) [53] , exisulind plus estramustine [54, 55] , and bortezomib (proteasome inhibitor) [56, 57] . In each case, the combination regimen did not increase rates of PSA and/or tumor response compared with standard docetaxel therapy.
trial end points
Overall survival is the key end point of phase III trials in CRPC. In phase II trials, alternative primary end points are employed to estimate clinical benefit, including rates of PSA decline, tumor response, pain response, or changes in bone lesions, although end point definitions have varied between trials. In phase II trials of docetaxel-based combination therapy, there has been no consensus on what constitutes a 'positive' trial and provides the justification for moving to phase III. Interpreting results for any agent combined with docetaxel is highly dependent on its mechanism of action. For example, cytotoxic agents are expected to reduce or eliminate disease, whereas noncytotoxic drugs are expected to prevent or delay disease progression and may not increase rates of PSA response. Similarly, a bone-targeted agent could provide clinical benefits without affecting tumor growth in soft tissue. Because of the biology of CRPC, a conventional tumor response end point, as applied in phase II trials of other solid tumors, is useful only in a small subset of patients with measurable disease and is not appropriate for the larger population with bone-only disease. Although various degrees of PSA decline have been found to correlate with survival in patients with CRPC [97, 98] , posttreatment declines in PSA likely explain only a small amount of the variation in outcomes of patients with CPRC and should not be used as the sole criterion for deciding to proceed with phase III testing.
To address various issues associated with design and selection of appropriate end points for trials in CRPC, guidelines were published in 2008 by the second Prostate Cancer Clinical Trial Working Group (PCWG2) [99] . In particular, PCWG2 recommended that phase II trials should focus more on time-to-event end points rather than measures of response, with the indication that a composite definition of PFS should be used, incorporating several measures (PSA, bone assessments, computed tomography scans, and symptom assessments). PCWG2 also specified that the various assessments of progression should be carried out at the same time points and that in the absence of rapid disease progression, a minimum of 12 weeks should be allowed to avoid premature interpretation of early, potentially misleading, clinical observations. PCWG2 also indicated that novel phase II trial designs (e.g. randomized designs, PFS as the primary end point) may be particularly informative and that the criteria to justify further development of a compound should be prespecified. The PCWG2 guidelines should help to increase consistency between future phase II trials and prioritize agents or combinations with the most promising results for phase III development.
In a recent pooled analysis of nine trials carried out by Cancer and Leukemia Group B involving men with CRPC without prior chemotherapy, immunotherapy, or other nonhormonal therapy, the predictive value of PFS at 3 and 6 months was evaluated. Progression was defined as either two or more new lesions on bone scan, PSA progression according to the earlier PSA Working Group 1 definition, or objective progression in lung, liver, nodes, or soft-tissue disease. This analysis found that median survival was lower in men who had progressed at either 3 months (9.2 versus 17.8 months, P < 0.0001) or 6 months (10.1 versus 19.6 months, P < 0.0001) than in those who were free from progression at these time points [100] . These findings indicate that a composite definition of progression may provide an intermediate end point for survival that could be particularly appropriate for phase II trials, although prospective validation is needed.
conclusions
Even with future improvements in antihormone therapy, a significant number of men with prostate cancer will develop metastatic CRPC and require chemotherapy. At present, docetaxel is the cornerstone of chemotherapy for CRPC. In phase II trials, combination treatment with docetaxel and several different agents has shown potential for increased efficacy and good tolerability compared with docetaxel alone. In other cases, however, combination treatment has provided no additional benefit or increased side-effects such as thromboembolic events. Completed phase III trials in CRPC to date have failed to improve on docetaxel's efficacy, although further phase III trials are in progress with docetaxel combined with agents with different mechanisms of action, including VEGF blockade (bevacizumab, aflibercept), SRC inhibition (dasatinib), and ET-A inhibition (atrasentan, zibotentan). Results are eagerly awaited to reveal if any of these combination strategies can increase patient survival compared with standard docetaxel treatment and thereby improve on the current standard of care for men with CRPC.
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